TAK-901

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameTAK-901
Drug Alias NameTAK-901
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora inhibitors
TargetsSerine/threonine-protein kinase Aurora
Therapy Area/IndicationsSolid tumoursPolycythemiaPrimary Myelofibrosis +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMillennium Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursPolycythemiaPrimary Myelofibrosis +[12] 

Other Information

ATC CodeN/A
Related LinksN/A